1.49
-0.0026(-0.17%)
Currency In USD
| Previous Close | 1.49 |
| Open | 1.49 |
| Day High | 1.54 |
| Day Low | 1.46 |
| 52-Week High | 1.84 |
| 52-Week Low | 0.65 |
| Volume | 722,241 |
| Average Volume | 2.68M |
| Market Cap | 116.88M |
| PE | -2.22 |
| EPS | -0.67 |
| Moving Average 50 Days | 1.08 |
| Moving Average 200 Days | 1.22 |
| Change | -0 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.03 as of February 05, 2025 at a share price of $1.49. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $513.79 as of February 05, 2025 at a share price of $1.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jan 28, 2025 8:11 PM GMT
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indica
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
GlobeNewswire Inc.
Jan 23, 2025 1:10 PM GMT
- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification – - Based on a Review of Un
SELLAS Announces Key Business Objectives for 2025
GlobeNewswire Inc.
Jan 08, 2025 1:20 PM GMT
- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 - - Approval of “tambiciclib” as